Open label, phase II randomized study of oral valganciclovir versus valacyclovir for prophylaxis of cytomegalovirus reactivation in patients receiving alemtuzumab (Campath)

Trial Profile

Open label, phase II randomized study of oral valganciclovir versus valacyclovir for prophylaxis of cytomegalovirus reactivation in patients receiving alemtuzumab (Campath)

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Jul 2012

At a glance

  • Drugs Valaciclovir; Valganciclovir
  • Indications Cytomegalovirus infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Dec 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top